Publikation

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

Wissenschaftlicher Artikel/Review - 23.01.2023

Bereiche
PubMed
DOI
Kontakt

Zitation
Núñez N, Berner F, Friebel E, Unger S, Wyss N. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 2023; 4:113-129.e7.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Med 2023; 4
Veröffentlichungsdatum
23.01.2023
eISSN (Online)
2666-6340
Seiten
113-129.e7
Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibitors (ICIs) are among the most promising treatment options for melanoma and non-small cell lung cancer (NSCLC). While ICIs can induce effective anti-tumor responses, they may also drive serious immune-related adverse events (irAEs). Identifying biomarkers to predict which patients will suffer from irAEs would enable more accurate clinical risk-benefit analysis for ICI treatment and may also shed light on common or distinct mechanisms underpinning treatment success and irAEs.